Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > July 19, 2024
Daily News
July 19, 2024
- Japan Panel Discusses Details of NIP for Shingles Jabs, OKs Inclusion of Prevenar 20
July 19, 2024
- Lilly’s Alzheimer’s Med Up for Health Ministry Panel Review on August 1
July 19, 2024
- Off-Year Scheme Drifting Away from Four-Minister Deal: JPMA Exec
July 19, 2024
- MHLW Pharma Management Director Hints at Addressing “Zero” Premium Issue
July 19, 2024
- Cancel or Postpone FY2025 Revision, or Scrap Off-Year Scheme: New JPA Chief
July 19, 2024
- FDA Clears IND for Japan JV’s Peptide-Based COVID Therapy
July 19, 2024
- Opdivo Extends Label for Frontline Bladder Cancer in South Korea
July 19, 2024
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…